HER2阴性-话题@MedSci

#HER2阴性#

38篇内容 | 1864人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1515459, encodeId=4a0915154591f, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=EUR J Cancer：贝伐单抗/紫杉醇与安慰剂/紫杉醇作为HER2阴性转移性乳腺癌一线治疗的临床试验中生物标志物分析, objectType=article, longId=125220, objectId=9c421252206b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c421252206b, replyNumber=0, likeNumber=69, createdTime=2018-01-02, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c421252206b, moduleTitle=EUR J Cancer：贝伐单抗/紫杉醇与安慰剂/紫杉醇作为HER2阴性转移性乳腺癌一线治疗的临床试验中生物标志物分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c421252206b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515458, encodeId=5f0d151545820, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=EUR J Cancer：贝伐单抗治疗HER2阴性转移性乳腺癌的基于实际和试验的成本效益分析, objectType=article, longId=124994, objectId=639912499456, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=639912499456, replyNumber=0, likeNumber=68, createdTime=2017-12-30, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=639912499456, moduleTitle=EUR J Cancer：贝伐单抗治疗HER2阴性转移性乳腺癌的基于实际和试验的成本效益分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=639912499456)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515457, encodeId=637a151545e1b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, objectType=article, longId=124108, objectId=397812410839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=397812410839, replyNumber=0, likeNumber=72, createdTime=2017-12-22, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=397812410839, moduleTitle=EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=397812410839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515456, encodeId=cfbf15154567e, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, objectType=article, longId=122620, objectId=45fb122620ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45fb122620ba, replyNumber=0, likeNumber=38, createdTime=2017-12-08, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45fb122620ba, moduleTitle=Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45fb122620ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515455, encodeId=be731515455bd, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？, objectType=article, longId=114639, objectId=ef9e114639a8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef9e114639a8, replyNumber=0, likeNumber=67, createdTime=2017-09-30, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef9e114639a8, moduleTitle=Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef9e114639a8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515454, encodeId=443f151545476, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？, objectType=article, longId=113380, objectId=f8ed113380c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8ed113380c7, replyNumber=0, likeNumber=53, createdTime=2017-09-21, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8ed113380c7, moduleTitle=β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8ed113380c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515453, encodeId=7f2c1515453b7, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期, objectType=article, longId=111335, objectId=5da0111335c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5da0111335c2, replyNumber=0, likeNumber=60, createdTime=2017-08-31, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5da0111335c2, moduleTitle=Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5da0111335c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515452, encodeId=3a521515452cd, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, objectType=article, longId=100383, objectId=5ff6100383d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff6100383d7, replyNumber=0, likeNumber=70, createdTime=2017-06-03, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff6100383d7, moduleTitle=NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff6100383d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515451, encodeId=1a58151545132, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, objectType=article, longId=79604, objectId=a2e5e960448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2e5e960448, replyNumber=0, likeNumber=77, createdTime=2016-10-10, rootId=0, userName=医者仁心, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2e5e960448, moduleTitle=NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2e5e960448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515450, encodeId=3f3b1515450a1, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Lancet Oncol：贝伐单抗对于非转移性HER2阴性炎性乳腺癌患者没有效果(BEVERLY-1研究), objectType=article, longId=65690, objectId=d9a86569064, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9a86569064, replyNumber=0, likeNumber=56, createdTime=2016-03-31, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9a86569064, moduleTitle=Lancet Oncol：贝伐单抗对于非转移性HER2阴性炎性乳腺癌患者没有效果(BEVERLY-1研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9a86569064)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515449, encodeId=44d2151544965, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法, objectType=article, longId=59361, objectId=aeb75936164, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aeb75936164, replyNumber=0, likeNumber=58, createdTime=2015-11-25, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aeb75936164, moduleTitle=Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aeb75936164)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515448, encodeId=b20415154483a, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）, objectType=article, longId=50644, objectId=48375064403, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48375064403, replyNumber=0, likeNumber=74, createdTime=2015-05-14, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48375064403, moduleTitle=Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48375064403)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515447, encodeId=81e0151544ea4, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), objectType=article, longId=41274, objectId=a319412e4e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a319412e4e0, replyNumber=0, likeNumber=93, createdTime=2014-10-16, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a319412e4e0, moduleTitle=Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a319412e4e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515446, encodeId=c8e115154468b, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, objectType=article, longId=40815, objectId=525640815a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=525640815a4, replyNumber=0, likeNumber=66, createdTime=2014-10-01, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=525640815a4, moduleTitle=维汀联合希罗达显著延长HER2阴性乳腺癌总生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=525640815a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515445, encodeId=67441515445b4, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, objectType=article, longId=38348, objectId=af3d38348b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af3d38348b5, replyNumber=0, likeNumber=67, createdTime=2014-07-30, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af3d38348b5, moduleTitle=索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af3d38348b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515444, encodeId=362215154447d, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, objectType=article, longId=36094, objectId=bf553609449, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf553609449, replyNumber=0, likeNumber=62, createdTime=2014-06-08, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf553609449, moduleTitle=ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf553609449)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515443, encodeId=7fd3151544317, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, objectType=article, longId=35032, objectId=208c35032c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=208c35032c3, replyNumber=0, likeNumber=61, createdTime=2014-05-22, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=208c35032c3, moduleTitle=ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=208c35032c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515442, encodeId=fc771515442b4, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Clin Cancer Res：ER阳性、HER2阴性的转移性乳腺癌（MBC）患者可从拉帕替尼获益？, objectType=article, longId=27171, objectId=f5ad2e17188, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5ad2e17188, replyNumber=0, likeNumber=70, createdTime=2013-11-29, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5ad2e17188, moduleTitle=Clin Cancer Res：ER阳性、HER2阴性的转移性乳腺癌（MBC）患者可从拉帕替尼获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5ad2e17188)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515441, encodeId=abe7151544185, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, objectType=article, longId=18292, objectId=0fad1829240, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fad1829240, replyNumber=0, likeNumber=87, createdTime=2013-05-08, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fad1829240, moduleTitle=Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fad1829240)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1515440, encodeId=3d5615154404f, content=<a href='/topic/show?id=73b18e42ac' target=_blank style='color:#2F92EE;'>#HER2阴性#</a>, objectTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, objectType=article, longId=13939, objectId=f49713939ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f49713939ce, replyNumber=0, likeNumber=63, createdTime=2013-01-06, rootId=0, userName=ms49895894946433513521, userId=e2cd10811473, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f49713939ce, moduleTitle=Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f49713939ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

HER2阴性

2020-05-29

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

EUR J Cancer：贝伐单抗/紫杉醇与安慰剂/紫杉醇作为HER2阴性转移性乳腺癌一线治疗的临床试验中生物标志物分析

2018-01-02

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

EUR J Cancer：贝伐单抗治疗HER2阴性转移性乳腺癌的基于实际和试验的成本效益分析

2017-12-30

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

EUR J CANCER：艾瑞布林联合吉西他滨与紫杉醇联合吉西他滨作为一线化疗方案治疗HER2阴性的转移性乳腺癌的多中心随机II期临床试验

2017-12-22

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Lancet oncol：Buparlisib联合氟维司群用于内分泌疗法和mTOR抑制剂治疗失败的雌激素受体阳性、HER2阴性的晚期乳腺癌患者的效果和安全性。

2017-12-08

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Int J Cancer：如何评估HER2阴性乳腺癌患者的长期预后？

2017-09-30

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

β受体拮抗剂是否可以延长晚期HER2阴性乳腺癌患者生存时间？

2017-09-21

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Ann Oncol：使用β－肾上腺素受体阻断剂能显著改善的HER2阴性的晚期乳腺癌患者的无进展生存期

2017-08-31

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

NEJM：卡培他滨用于HER2阴性侵袭性乳腺癌

2017-06-03

医者仁心 (审核中...)

前往app查看评论内容

#HER2阴性#

NEJM：HR阳性HER2阴性的晚期乳腺癌，ribociclib联合来曲唑可明显延长患者的无进展生存期

2016-10-10

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Lancet Oncol：贝伐单抗对于非转移性HER2阴性炎性乳腺癌患者没有效果(BEVERLY-1研究)

2016-03-31

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Lancet Oncol：可考虑将S-1作为HER2阴性的转移性乳腺癌的一线治疗方法

2015-11-25

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Lancet Oncol：贝伐单抗添加到新辅助化疗对HER2阴性乳腺癌效果（ARTemis试验）

2015-05-14

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Lancet Oncol：贝伐珠单抗+二线化疗能改善HER2阴性乳腺癌PFS (TANIA研究)

2014-10-16

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

维汀联合希罗达显著延长HER2阴性乳腺癌总生存期

2014-10-01

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

索拉非尼不能延长HER2阴性乳腺癌患者无进展生存期（RESILIENCE研究）

2014-07-30

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

ASCO 2014：辅助化疗+贝伐珠单抗未使HER2阴性乳腺癌患者获益

2014-06-08

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

ASCO 2014：贝伐单抗在HER2阴性乳腺癌辅助治疗中失利（E5103研究）

2014-05-22

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Clin Cancer Res：ER阳性、HER2阴性的转移性乳腺癌（MBC）患者可从拉帕替尼获益？

2013-11-29

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Clin Cancer Res. ：在HER2阴性乳腺癌中鉴定出HER2阳性干细胞

2013-05-08

ms49895894946433513521 (审核中...)

前往app查看评论内容

#HER2阴性#

Clin Cancer Res：研究揭示HER2阴性乳腺癌新的矛盾特征

2013-01-06

科室
- - 订阅+
  - 更多科室
工具
服务